Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 22;13(3):403.
doi: 10.3390/cancers13030403.

Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study

Alexandra L Farrall  1 , Justine R Smith  1
Affiliations

Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study

Alexandra L Farrall et al. Cancers (Basel). .

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare brain cancer that remains challenging to study. Epidemiology of PCNSL in the Australian population, which is racially and ethnically diverse, has not been examined previously. Using ICD-O-3.1 Morphology and Topography Codes to identify cases, we analyzed complete datasets from the comprehensive Australian Cancer Database (1982-2014, adults aged ≥ 20 years) to establish incidence rates and trends of PCNSL, and to define survival outcomes of individuals diagnosed with PCNSL, including the predominant diffuse large B-cell lymphoma (DLBCL) type. Age-standardized incidence of PCNSL increased by an average annual 6.8% percent over the study period, with current incidence of 0.43 (95% confidence interval, 0.41-0.46) per 100,000 person-years, in comparison to 21.89 (21.41-22.38) per 100,000 person-years for non-CNS lymphoma. Increase in incidence was characterized by an acute rise between 1996 and 1999, was more pronounced with increasing age, and was driven by increasing incidence of DLBCL. Overall survival for persons diagnosed with PCNSL improved significantly across the study period, with 5-year survival probability increasing from 0.21 (95% confidence interval, 0.16-0.26) to 0.33 (0.30-0.36), and median survival increasing from 318 to 600 days, between 1982-1999 and 2000-2014. Increase in survival was significantly higher for persons with DLBCL versus non-DLBCL PCNSL, but substantially lower than that for persons with non-CNS lymphoma, who had a 5-year survival probability of 0.62 (0.62-0.62) and a median survival of 3388 days in 2000-2014. This study links increasing incidence of PCNSL in Australia to increasing incidence of DLCBL, including in younger adults, and highlights the improving, but low, survival outcome of this cancer.

Keywords: Lymphoma; central nervous system; diffuse large B-cell lymphoma; incidence; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Age-standardized incidence rates over time for Australian adults with (A) primary central nervous system lymphoma (PCNSL) and non-CNS lymphoma; (B) diffuse large B-cell lymphoma (DLBCL) and other lymphomas (non-DLBCL) within the CNS and non-CNS compartments; (C) CNS DLBCL, presented by age group at diagnosis. Shapes indicate observed incidence rates, and continuous lines indicate modeled incidence rates.
Figure 2
Figure 2
Probability of survival for up to 5 years in Australian adults with (A) primary central nervous system lymphoma (PCNSL) and non-CNS lymphoma; (B) diffuse large B-cell lymphoma (DLBCL) within the CNS and non-CNS compartments; (C) CNS DLBCL presented by age group at diagnosis.
See this image and copyright information in PMC

References

    1. Grommes C., DeAngelis L.M. Primary CNS Lymphoma. J. Clin. Oncol. 2017;35:2410–2418. doi: 10.1200/JCO.2017.72.7602. - DOI - PMC - PubMed
    1. Ostrom Q.T., Gittleman H., Liao P., Vecchione-Koval T., Wolinsky Y., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19:v1–v88. doi: 10.1093/neuonc/nox158. - DOI - PMC - PubMed
    1. Rigau V., Zouaoui S., Mathieu-Daudé H., Darlix A., Maran A., Trétarre B., Bessaoud F., Bauchet F., Attaoua R., Fabbro-Peray P., et al. French brain tumor database: 5-year histological results on 25,756 cases. Brain Pathol. 2011;21:633–644. doi: 10.1111/j.1750-3639.2011.00491.x. - DOI - PMC - PubMed
    1. Farrall A.L., Smith J.R. Eye involvement in primary central nervous system lymphoma. Surv. Ophthalmol. 2020;65:548–561. doi: 10.1016/j.survophthal.2020.02.001. - DOI - PubMed
    1. Kasamon Y.L., Ambinder R.F. AIDS-related primary central nervous system lymphoma. Hematol. Oncol. Clin. N. Am. 2005;19:665–687. doi: 10.1016/j.hoc.2005.05.004. - DOI - PubMed

LinkOut - more resources